Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9%
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- These Are the Stocks Reporting Earnings Today – April 29, 2026
- Notable companies reporting before tomorrow’s open
- GSK announces U.S. FDA accepted priority review, granted BTD for bepirovirsen
- Ionis partner GSK announces bepirovirsen NDA accepted for priority review
- GSK announces efimosfermin granted BTE by U.S. FDA, PRIME by EMA